In vitro comparison of two NONOates (novel nitric oxide donors) on rat pulmonary arteries

European Journal of Pharmacology

Volumn 356, Issue 1, 1998, Pages 49-57

  Homer, Kerry ^a   Wanstall, Janet ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

MAHMA NONOate; Nitric oxide donor; NONOate; Pulmonary artery, rat; Pulmonary hypertension; Spermine NONOate

Indexed keywords

DIAZENIUMDIOLATE DERIVATIVE; NITRIC OXIDE DONOR; SPASMOLYTIC AGENT; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENZYME INHIBITORS; GUANYLATE CYCLASE; HYDRAZINES; MALE; MUTAGENS; NITRIC OXIDE; NITROGEN OXIDES; NITROGLYCERIN; OXADIAZOLES; PULMONARY ARTERY; QUINOXALINES; RATS; RATS, WISTAR; SPERMINE; VASODILATION; VASODILATOR AGENTS;

EID: 0032575587     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00511-1     Document Type: Article

References (32)

1. Adrie C., Ichinose F., Holzmann A., Keefer L.K., Hurford W.E., Zapol W.M. Pulmonary vasodilation by nitric oxide gas and prodrug aerosols in acute pulmonary hypertension. J. Appl. Physiol. 84:1998;435-441.
2. Archer S.L., Huang J.M., Hampl V., Nelson D.O., Schultz P.J., Weir E.K. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A. 91:1994;7583-7587.
3. Archer S.L., Huang J.M., Reeve H.L., Hampl V., Tolarova S., Michelakis E., Weir E.K. Differential distribution of electrophysiologically distinct myocytes in conduit and resistance arteries determines their response to nitric oxide and hypoxia. Circ. Res. 78:1996;431-442.
4. Barnes P.J., Liu S.F. Regulation of pulmonary vascular tone. Pharmacol. Rev. 47:1995;87-131.
5. Bauer J.T., Booth B.P., Fung H.L. Nitric oxide donors: biochemical pharmacology and therapeutics. Adv. Pharmacol. 34:1995;361-381.
6. Brilli R.J., Krafte-Jacobs B., Smith D.J., Roselle D., Passerini D., Vromen A., Moore L., Szabo C., Salzman A. Intratracheal instillation of a novel NO/nucleophile adduct selectively reduces pulmonary hypertension. J. Appl. Physiol. 83:1997;1968-1975.
7. Brunner F., Schmidt K., Nielsen E.B., Mayer B. Novel guanylyl cyclase inhibitor potently inhibits cyclic GMP accumulation in endothelial cells and relaxation of bovine pulmonary artery. J. Pharmacol. Exp. Ther. 277:1996;48-53.
8. De Meis L. Relaxing effect of spermine and spermidine on intact and glycerol-treated muscle. Am. J. Physiol. 212:1967;92-96.
9. Dinh-Xuan A.T., Higenbottam T.W., Clelland C.A., Pepke-Zaba J., Cremona G., Butt A.Y., Large S.R., Weels F.C., Wallwork J. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. New Engl. J. Med. 324:1991;1539-1547.
10. Diodati J.G., Quyyumi A.A., Keefer L.K. Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: Hemodynamic effect in the rabbit. J. Cardiovasc. Pharmacol. 22:1993;287-292.
11. Feelisch, M., Stamler, J.S., 1996. Donors of nitrogen oxides. In: Feelisch, M., Stamler, J. (Eds.), Methods in nitric oxide research. Wiley, Chichester, pp. 71-115.
12. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol. Pharmacol. 48:1995;184-188.
13. Hampl V., Tristani-Firouzi M., Hutsell T.C., Archer S.L. Nebulized nitric oxide/nucleophile adduct reduces chronic pulmonary hypertension. Cardiovasc. Res. 31:1996;55-62.
14. Henry P.J., Horowitz J.D., Louis W.J. Nitroglycerine-induced tolerance affects multiple sites in the organic nitrate bioconversion cascade. J. Pharmacol. Exp. Ther. 248:1989;762-768.
15. Homer K.L., Gambino A., Wanstall J.C. A comparison of two NONOates (novel nitric oxide donors) on rat pulmonary artery preparations. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol. 4:1997;65. (Abstract).
16. Hrabie J.A., Klose J.R., Wink D.A., Keefer L.K. New nitric oxide-releasing zwitterions derived from polyamines. J. Org. Chem. 58:1993;1472-1476.
17. Keefer L.K., Nims R.W., Davies K.M., Wink D.A. 'NONOates' (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 268:1996;281-293.
18. Kelm, M., Yoshida, K., 1996. Metabolic fate of nitric oxide and related N-oxides. In: Feelisch, M., Stamler, J. (Eds.), Methods in nitric oxide research. Wiley, Chichester, pp. 47-58.
19. Krebs C., Escuyer M., Urak G., Zimpfer M., Germann P. Technological basis for NO application and environmental security. Acta. Anaesthesiol. Scand. 109:1996;84-87.
20. Kukovetz W.R., Holzmann S. Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries. J. Cardiovasc. Pharmacol. 14:1989;S40-S46.
21. Longhi R., Ragsdale R.O., Drago R.S. Reactions of nitrogen(II) oxide with miscellaneous Lewis bases. Inorg. Chem. 1:1962;768-770.
22. Maragos C., Morley D., Wink D.A., Dunams T.M., Saavedra J.E., Hoffman A., Bove A.A., Isaac L., Hrabie J., Keefer L. Complexes of NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J. Med. Chem. 34:1991;3242-3247.
23. Morley D., Maragos C., Zhang X., Boignon M., Wink D., Keefer L.K. Mechanism of vascular relaxation induced by the nitric oxide (NO)/nucleophile complexes, a new class of NO-based vasodilators. J. Cardiovasc. Pharmacol. 21:1993;670-676.
24. Ragsdale R.O., Karstetter B.R., Drago R.S. Decomposition of the adducts of diethylamine and isopropylamine with nitrogen(II) oxide. Inorg. Chem. 4:1965;420-422.
25. Schrammel A., Behrends S., Schmidt K., Koesling D., Mayer B. Characterisation of 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol. 50:1996;1-5.
26. Van de Voorde J., Claeys M., Leusen I. Relaxations to endothelium-derived relaxing factor and the metabolite of molsidomine (SIN-1), in the aorta and the hindquarters of the rat. J. Cardiovasc. Pharmacol. 14:1989;S55-S61.
27. Vanderford P.A., Wong J., Chang R., Keefer L.K., Soifer S.J., Fineman J.R. Diethylamine/nitric oxide (NO) adduct, an NO donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs. J. Cardiovasc. Pharmacol. 23:1994;113-119.
28. Wanstall J.C., O'Donnell S.R. Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur. J. Pharmacol. 176:1990;159-168.
29. Wanstall J.C., Hughes I.E., O'Donnell S.R. Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension. Br. J. Pharmacol. 114:1995;109-114.
30. Wanstall J.C., Kay C.S., O'Donnell S.R., Wilson K., Cole P.H., Matar K. Evaluation of bosentan, pinacidil and nitroprusside on human pulmonary arteries: comparison with rat pulmonary arteries. Fundam. Clin. Pharmacol. 11:1997;584-591.
31. Wanstall J.C., Kaye J.A., Gambino A. The in vitro pulmonary vascular effects of FK409 (nitric oxide donor): a study in normotensive and pulmonary hypertensive rats. Br. J. Pharmacol. 121:1997;280-286.
32. Zapol W.M. Inhaled nitric oxide. Acta Anaesthesiol. Scand. Suppl. 109:1996;81-83.